FDA-cleared profile

AudaxCeph Cephalogram Analysis Software

Audax d.o.o. · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: AudaxCeph Cephalogram Analysis Software assists specialized dental practices with storing and presenting patient cephalogram images and treatment planning through landmark digitization, tracing, measurements, superimpositions, and visual treatment objectives; trained and licensed practitioners remain responsible for interpretation.

Clinical role
Stores or presents cephalograms, digitizes landmarks, traces structures, calculates measurements, and supports orthodontic planning and superimposition review.
Images and patients
X-ray/Radiography · Dental/maxilla/mandible
Key limitation
Keep in mind: The source image is acquired separately; results depend on trained and licensed practitioners, supported file formats, image quality, and the exact local desktop or cloud configuration, and the software does not replace professional diagnosis or planning judgment.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: AudaxCeph Cephalogram Analysis Software assists specialized dental practices with storing and presenting patient cephalogram images and treatment planning through landmark digitization, tracing, measurements, superimpositions, and visual treatment objectives; trained and licensed practitioners remain responsible for interpretation.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Dental/maxilla/mandible Input: Two-dimensional cephalogram images in BMP, JPG, JPEG, PNG, or TIFF formats.
  • Who uses it?Intended users: Trained and licensed orthodontists, dentists, and other specialty dental professionals.
  • What does the software produce?Output: Landmark traces, measurements, custom analyses, superimpositions, and visual treatment-objective planning views.
  • What is its most important limitation?Key limitation: The source image is acquired separately; results depend on trained and licensed practitioners, supported file formats, image quality, and the exact local desktop or cloud configuration, and the software does not replace professional diagnosis or planning judgment.

Clinical takeaway. Clinical role: AudaxCeph Cephalogram Analysis Software assists specialized dental practices with storing and presenting patient cephalogram images and treatment planning through landmark digitization, tracing, measurements, superimpositions, and visual treatment objectives; trained and licensed practitioners remain responsible for interpretation.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical testing, including software verification tests covering unit, performance, manual, integration, and system and regression testing, with all testing meeting the predetermined acceptance values. An automatic landmark detection accuracy study, with landmarks reviewed by orthodontists, met all acceptance criteria: MRE ≤ 1.5 mm (lateral) and ≤ 2.5 mm (frontal PA). No clinical testing was required to support substantial equivalence. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
AudaxCeph Cephalogram Analysis Software assists specialized dental practices with storing and presenting patient cephalogram images and treatment planning through landmark digitization, tracing, measurements, superimpositions, and visual treatment objectives; trained and licensed practitioners remain responsible for interpretation.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Stores or presents cephalograms, digitizes landmarks, traces structures, calculates measurements, and supports orthodontic planning and superimposition review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Two-dimensional cephalogram images in BMP, JPG, JPEG, PNG, or TIFF formats.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Landmark traces, measurements, custom analyses, superimpositions, and visual treatment-objective planning views.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Specialized dental and orthodontic practices.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained and licensed orthodontists, dentists, and other specialty dental professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The source image is acquired separately; results depend on trained and licensed practitioners, supported file formats, image quality, and the exact local desktop or cloud configuration, and the software does not replace professional diagnosis or planning judgment.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports non-clinical testing, including software verification tests covering unit, performance, manual, integration, and system and regression testing, with all testing meeting the predetermined acceptance values. An automatic landmark detection accuracy study, with landmarks reviewed by orthodontists, met all acceptance criteria: MRE ≤ 1.5 mm (lateral) and ≤ 2.5 mm (frontal PA). No clinical testing was required to support substantial equivalence. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Non-clinical testing, including software verification tests, evaluated: • Unit testing • Performance Testing • Manual Testing • Integration Testing • System and Regression Testing" … "All testing has met the predetermined acceptance values.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical testing, including software verification tests covering unit, performance, manual, integration, and system and regression testing, with all testing meeting the predetermined acceptance values. An automatic landmark detection accuracy study, with landmarks reviewed by orthodontists, met all acceptance criteria: MRE ≤ 1.5 mm (lateral) and ≤ 2.5 mm (frontal PA). No clinical testing was required to support substantial equivalence. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Non-clinical testing, including software verification tests, evaluated: • Unit testing • Performance Testing • Manual Testing • Integration Testing • System and Regression Testing" … "All testing has met the predetermined acceptance values.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Automatic landmark mean radial error acceptance criterion, lateral

1.5 mm

  • EndpointMaximum accepted mean radial error
  • PopulationLateral cephalogram landmarking
  • Tested versionAudaxCeph Cephalogram Analysis Software configuration described in K243005

Automatic landmark mean radial error acceptance criterion, frontal PA

2.5 mm

  • EndpointMaximum accepted mean radial error
  • PopulationFrontal posteroanterior cephalogram landmarking
  • Tested versionAudaxCeph Cephalogram Analysis Software configuration described in K243005

K243005 FDA evidence package for AudaxCeph Cephalogram Analysis Software

  • DesignFDA 510(k) software verification and validation for the exact cephalogram-analysis configuration.
  • PopulationSupported two-dimensional cephalogram image files and software functions for landmarking, tracing, measurement, and planning.
  • Scopeexact submission
  • Tested versionAudaxCeph Cephalogram Analysis Software configuration described in K243005
  • IndependenceSponsor or vendor study

K243005

The FDA material reports acceptance criteria for automatic landmarking and states that clinical testing was not required.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K243005 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Two-dimensional cephalogram images in BMP, JPG, JPEG, PNG, or TIFF formats.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K243005: AudaxCeph Cephalogram Analysis Software

  2. Routing

    Source context, not route validation: The FDA material describes import of supported image files and local desktop or browser workflows; no patient-acquisition interface is part of the software.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K243005: AudaxCeph Cephalogram Analysis Software

  3. AI processing

    Source context, not route validation: The FDA material describes local PC desktop editions and a browser-based cloud WeDoCeph workflow; current hosting, data retention, security, and site configuration remain unverified.

    Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K243005: AudaxCeph Cephalogram Analysis Software

  4. Returned objects

    Source context, not route validation: Landmark traces, measurements, custom analyses, superimpositions, and visual treatment-objective planning views.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K243005: AudaxCeph Cephalogram Analysis Software

  5. Viewer/worklist/report

    Unresolved route: Landmark traces, measurements, custom analyses, superimpositions, and visual treatment-objective planning views.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K243005: AudaxCeph Cephalogram Analysis Software

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA material describes local PC desktop editions and a browser-based cloud WeDoCeph workflow; current hosting, data retention, security, and site configuration remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04

This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Integration
The FDA material describes import of supported image files and local desktop or browser workflows; no patient-acquisition interface is part of the software.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Training
Only Trained and licensed orthodontists, dentists, and other specialty dental professionals should operate or interpret the product; local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K243005 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: The source image is acquired separately; results depend on trained and licensed practitioners, supported file formats, image quality, and the exact local desktop or cloud configuration, and the software does not replace professional diagnosis or planning judgment.
  • Exact FDA submission
  • Checked 2026-09-04

Buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K243005 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The FDA material describes local PC desktop editions and a browser-based cloud WeDoCeph workflow; current hosting, data retention, security, and site configuration remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA material describes import of supported image files and local desktop or browser workflows; no patient-acquisition interface is part of the software.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The source image is acquired separately; results depend on trained and licensed practitioners, supported file formats, image quality, and the exact local desktop or cloud configuration, and the software does not replace professional diagnosis or planning judgment.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K243005 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243005
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Dental/maxilla/mandible
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-05-30
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
32Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The discovery snapshot contains no PubMed or ClinicalTrials.gov candidates for K243005; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

6 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K243005: AudaxCeph Cephalogram Analysis Software

    U.S. Food and Drug Administration - Published 2025-05-30 - Accessed 2026-09-04

    Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K243005 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K250914

MediAI-BA

Crescom Co., Ltd.

Authorized purpose: View and quantify bone age from 2D posteroanterior left-hand radiographs to aid pediatric radiologists assessing patients aged 2-18 years.

Modality
X-ray/Radiography
Anatomy
Left hand and wrist; skeletal maturity/bone age
Decision
2025-12-18
FDA-cleared K252086

DTX Studio Assist

Nobel Biocare C/O Medicim NV

Authorized purpose: Analyzes two-dimensional bitewing and periapical radiographs of permanent teeth in patients aged 15 and older to identify and localize caries, calculus, periapical radiolucency, root canal filling deficiency, discrepancy at an existing restoration margin, and bone loss; also supports alveolar bone-level measurement and restoration/dental-anatomy segmentation as an adjunct to dentist review.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-11-17
FDA-cleared K250264

SugarBug (1.x)

Bench7, Inc.

Authorized purpose: Provides automated concurrent-read detection and segmentation of caries on bitewing radiographs in patients 18 and older, adding information for the dentist while requiring complete dentist review and judgment.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-11-07
FDA-cleared K251747

VEA Align; spineEOS

EOS imaging

Authorized purpose: VEA Align is cloud-based software for orthopedic applications in adult and pediatric populations using two-dimensional X-ray images from EOS imaging systems to display interactive landmarks and assess patient-specific global alignment, with angle and length measurements for spinal deformities, degenerative diseases, and lower-limb alignment disorders or deformities. It is suitable for patients aged 7 years and older. spineEOS assists healthcare professionals with preoperative planning of spine surgery using EOS images, associated three-dimensional datasets, measurements, and patient-specific surgical-planning tools.

Modality
X-ray/Radiography
Anatomy
Spine and lower-limb alignment; frontal and lateral EOS images and associated 3D datasets
Decision
2025-08-15

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history